3EE0 Stock Overview
Develops drugs for inflammatory diseases and cancer in Sweden and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kancera AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.13 |
| 52 Week High | SEK 0.48 |
| 52 Week Low | SEK 0.095 |
| Beta | 1.7 |
| 11 Month Change | -13.19% |
| 3 Month Change | 2.46% |
| 1 Year Change | -55.83% |
| 33 Year Change | -85.22% |
| 5 Year Change | -79.97% |
| Change since IPO | -98.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3EE0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.3% | 0.5% | -1.4% |
| 1Y | -55.8% | -16.2% | 11.8% |
Return vs Industry: 3EE0 underperformed the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: 3EE0 underperformed the German Market which returned 13.9% over the past year.
Price Volatility
| 3EE0 volatility | |
|---|---|
| 3EE0 Average Weekly Movement | 21.5% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3EE0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3EE0's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5 | Peter Selin | www.kancera.com |
Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy.
Kancera AB (publ) Fundamentals Summary
| 3EE0 fundamental statistics | |
|---|---|
| Market cap | €15.04m |
| Earnings (TTM) | -€4.56m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.3x
P/E RatioIs 3EE0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3EE0 income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 53.07m |
| Earnings | -SEK 53.07m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 15, 2024
| Earnings per share (EPS) | -0.44 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 3EE0 perform over the long term?
See historical performance and comparison